- Home
- BIIB vs NTRS Comparison
BIIB vs NTRS Comparison
Compare BIIB & NTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- NTRS
- Stock Information
- Founded
- BIIB 1978
- NTRS 1889
- Country
- BIIB United States
- NTRS United States
- Employees
- BIIB N/A
- NTRS N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- NTRS Major Banks
- Sector
- BIIB Health Care
- NTRS Finance
- Exchange
- BIIB Nasdaq
- NTRS Nasdaq
- Market Cap
- BIIB 18.8B
- NTRS N/A
- IPO Year
- BIIB 1991
- NTRS N/A
- Fundamental
- Price
- BIIB $127.50
- NTRS $123.60
- Analyst Decision
- BIIB Buy
- NTRS Hold
- Analyst Count
- BIIB 27
- NTRS 12
- Target Price
- BIIB $188.17
- NTRS $113.00
- AVG Volume (30 Days)
- BIIB 1.2M
- NTRS 2.9M
- Earning Date
- BIIB 07-31-2025
- NTRS 07-23-2025
- Dividend Yield
- BIIB N/A
- NTRS 2.41%
- EPS Growth
- BIIB 26.39
- NTRS 137.54
- EPS
- BIIB 10.12
- NTRS 10.76
- Revenue
- BIIB $9,816,400,000.00
- NTRS $8,577,100,000.00
- Revenue This Year
- BIIB N/A
- NTRS N/A
- Revenue Next Year
- BIIB N/A
- NTRS $3.86
- P/E Ratio
- BIIB $12.69
- NTRS $11.56
- Revenue Growth
- BIIB 1.59
- NTRS 28.50
- 52 Week Low
- BIIB $110.04
- NTRS $80.81
- 52 Week High
- BIIB $236.48
- NTRS $133.00
- Technical
- Relative Strength Index (RSI)
- BIIB 45.02
- NTRS 56.94
- Support Level
- BIIB $132.37
- NTRS $125.77
- Resistance Level
- BIIB $137.84
- NTRS $128.12
- Average True Range (ATR)
- BIIB 4.12
- NTRS 2.97
- MACD
- BIIB 0.01
- NTRS -0.74
- Stochastic Oscillator
- BIIB 25.82
- NTRS 35.04
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.